• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025

    5/8/25 8:35:00 AM ET
    $BLTE
    $COE
    $HCM
    $IH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Real Estate
    Get the next $BLTE alert in real time by email

    NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Thursday, May 15, 2025 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States.

    Representatives from participating companies based in China, Hong Kong, Philippines, Denmark, Germany, South Africa, Switzerland, Sweden, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies.

    There is no fee for participants to log in, attend live presentations and/or ask questions.

    Pre-registration is suggested. Please register here: www.adr.db.com/dbvic

    Conference Agenda May 15th, 2025 (US Eastern Standard Time):

    • 8:00 AM: Bavarian Nordic A/S ((Nasdaq Copenhagen: BAVA, OTC:BVNRY)  
    • 8:30 AM: Viomi Technology Co., Ltd (NASDAQ:VIOT)
    • 9:00 AM: Infineon Technologies AG ((Xetra: IFX, OTC:IFNNY)
    • 9:30 AM: Clicks Group Ltd ((JSE: CLS, OTC:CLCGY)
    • 10:00 AM: First Pacific Company Ltd ((HKEX: 142, OTC:FPAFY)
    • 10:30 AM: HUTCHMED (China) Limited (AIM: HCM, NASDAQ:HCM, and HKEX:13)
    • 11:00 AM: 51Talk Online Education Group (NYSE:COE)
    • 11:30 AM: Yiren Digital Ltd. (NYSE:YRD)
    • 12:00 PM: ABB Ltd. ((SIX: ABBN, OTC:ABBNY)
    • 12:30 PM: Belite Bio, Inc  (NASDAQ:BLTE)
    • 13:00 PM: Epiroc AB ((Nasdaq Stockholm: EPIA, OTC:EPOAY)
    • 13:30 PM: International Airlines Group ((LSE: IAG, MAD: IAG, OTC:ICAGY)
    • 14:00 PM: BDO Unibank, Inc ((PSE: BDO, OTC:BDOUY)
    • 14:30 PM: iHuman Inc. (NYSE:IH)

    The presentations will be available for replay after the conference.

    In addition to specializing in administering cross-border equity structures such as American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. The Bank offers a broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

    For further information, please contact:

    Dylan Riddle

    Deutsche Bank AG

    Press & Media Relations

    Tel. +12122504982

    Cell. +1(904)3866481

    Email [email protected]

    Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany's leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

    Deutsche Bank is sponsoring the Deutsche Bank Depositary Receipt Investor Conference solely for informational purposes. Deutsche Bank does not prepare, review, approve or edit any presentations, statements, documents or other information or materials, whether in written, electronic or verbal form, provided by any company participating in such conference, and disclaims any responsibility for the accuracy or adequacy of any such information or materials. Deutsche Bank is not promoting, endorsing or recommending any company participating in the conference.

    The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act") on Form F-6. The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant as to or guarantee the accuracy or completeness of the details contained herein and does not undertake an obligation to update or amend this information. Deutsche Bank, its subsidiaries and/or affiliates disclaims any and all liability to fullest extent permitted by law, whether arising in tort, contract or otherwise, which any of them might otherwise have in respect of the above information. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities in the United States, nor does it constitute an offer or solicitation to any person in any other jurisdiction. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© May 2025 Deutsche Bank AG. All rights reserved.



    Primary Logo

    Get the next $BLTE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BLTE
    $COE
    $HCM
    $IH

    CompanyDatePrice TargetRatingAnalyst
    HUTCHMED (China) Limited
    $HCM
    5/13/2025Buy → Hold
    HSBC Securities
    Belite Bio Inc
    $BLTE
    12/14/2023$60.00Buy
    Maxim Group
    HUTCHMED (China) Limited
    $HCM
    11/24/2023Hold → Buy
    Deutsche Bank
    Belite Bio Inc
    $BLTE
    7/28/2023$43.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    7/26/2023$25.00Outperform
    SVB Securities
    iHuman Inc.
    $IH
    12/30/2022$3.10Buy
    Citigroup
    Belite Bio Inc
    $BLTE
    8/1/2022$58.00Buy
    H.C. Wainwright
    HUTCHMED (China) Limited
    $HCM
    5/4/2022Buy → Hold
    Deutsche Bank
    More analyst ratings

    $BLTE
    $COE
    $HCM
    $IH
    SEC Filings

    See more
    • SEC Form 6-K filed by HUTCHMED (China) Limited

      6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

      7/3/25 6:10:55 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by HUTCHMED (China) Limited

      6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

      7/2/25 6:07:02 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Belite Bio Inc

      6-K - BELITE BIO, INC (0001889109) (Filer)

      7/2/25 6:02:58 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLTE
    $COE
    $HCM
    $IH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HUTCHMED downgraded by HSBC Securities

      HSBC Securities downgraded HUTCHMED from Buy to Hold

      5/13/25 3:20:36 PM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Belite Bio with a new price target

      Maxim Group initiated coverage of Belite Bio with a rating of Buy and set a new price target of $60.00

      12/14/23 8:06:18 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED upgraded by Deutsche Bank

      Deutsche Bank upgraded HUTCHMED from Hold to Buy

      11/24/23 7:13:23 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLTE
    $COE
    $HCM
    $IH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HUTCHMED to Announce 2025 Half-Year Financial Results

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). HUTCHMED management will host two webcast presentations for analysts and investors to discuss the interim results, followed by Q&A sessions. The English webcast will be held on Thursday, August 7, 2025, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 1:30 am BST on Friday

      7/3/25 4:30:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

      -  500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of enrollment in the PHOENIX trial, a global, 24-month Phase 3 pivotal trial evaluating the safety and tolerability of Tinlarebant and its potential to reduce atrophic lesion growth rate in patients diagnosed with geographic atrophy (GA) in dry age-related macular degeneration (AMD). "

      7/2/25 3:00:00 AM ET
      $BLTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

      — Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy — — The only all-oral combination treatment option for these patients — — Consistent benefit regardless of first-line EGFR inhibitor therapy — HONG KONG, SHANGHAI and FLORHAM PARK, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application ("NDA") for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) has been granted approval by the China National Medical Products Administration ("NMPA") for the treatment of patients with loca

      6/30/25 4:30:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLTE
    $COE
    $HCM
    $IH
    Leadership Updates

    Live Leadership Updates

    See more
    • 51Talk Online Education Group to Present on the Emerging Growth Conference on June 17, 2025.

      51Talk Online Education Group invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference. SINGAPORE, June 12, 2025 /PRNewswire/ -- 51Talk Online Education Group (the "Company") (NYSE:COE), a global online education platform with core expertise in English education, is pleased to announce that it has been invited to present on the Emerging Growth Conference on June 17, 2025. The next Emerging Growth Conference is presenting on June 17, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's inve

      6/12/25 5:30:00 AM ET
      $COE
      Other Consumer Services
      Real Estate
    • HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr Wong retired as

      3/5/25 5:00:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viomi Technology Co., Ltd Appoints New President of Operations to Promote High-quality Business Development

      GUANGZHOU, China, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced the appointment of Mr. Guang Wu as President of Operations, effective December 4, 2024. In this role, Mr. Wu will focus on driving high-quality business development and enhancing operational efficiency. Mr. Wu brings over 20 years of experience in business development and marketing within the domestic home appliances and home furnishing industry. Prior to joining Viomi, he served as Vice President and General Manager of Domestic Marketing at Sleemon Group. Before that, he managed domestic m

      12/4/24 4:00:00 AM ET
      $VIOT
      Consumer Electronics/Appliances
      Consumer Discretionary

    $BLTE
    $COE
    $HCM
    $IH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by 51Talk Online Education Group

      SC 13D/A - 51Talk Online Education Group (0001659494) (Subject)

      12/17/24 4:07:04 PM ET
      $COE
      Other Consumer Services
      Real Estate
    • Amendment: SEC Form SC 13G/A filed by Viomi Technology Co. Ltd

      SC 13G/A - Viomi Technology Co., Ltd (0001742770) (Subject)

      11/12/24 6:35:53 AM ET
      $VIOT
      Consumer Electronics/Appliances
      Consumer Discretionary
    • Amendment: SEC Form SC 13D/A filed by 51Talk Online Education Group

      SC 13D/A - 51Talk Online Education Group (0001659494) (Subject)

      10/10/24 6:45:35 AM ET
      $COE
      Other Consumer Services
      Real Estate

    $BLTE
    $COE
    $HCM
    $IH
    Financials

    Live finance-specific insights

    See more
    • iHuman Inc. Announces First Quarter 2025 Unaudited Financial Results

      BEIJING, June 26, 2025 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Revenues were RMB210.4 million (US$29.0 million), compared with RMB235.0 million in the same period last year.Gross profit was RMB143.8 million (US$19.8 million), compared with RMB168.1 million in the same period last year.Operating income was RMB21.6 million (US$3.0 million), compared with

      6/26/25 6:12:00 AM ET
      $IH
      Other Consumer Services
      Real Estate
    • Yiren Digital Reports First Quarter 2025 Financial Results

      BEIJING, June 12, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), an AI-powered platform providing a comprehensive suite of financial and lifestyle services in Asia, today announced its unaudited financial results for the quarter ended March 31, 2025. First Quarter 2025 Operational Highlights Financial Services Business Total loans facilitated in the first quarter of 2025 reached RMB15.2 billion (US$2.1 billion), representing a slight decrease of 1% from RMB15.4 billion in the fourth quarter of 2024 and compared to RMB11.9 billion in the same period of 2024.Cumulative number of borrowers served reached 12,909,436 as of March 31, 2025, representing an

      6/12/25 5:30:00 AM ET
      $YRD
      Finance: Consumer Services
      Finance
    • 51Talk Online Education Group Announces First Quarter 2025 Results

      SINGAPORE, June 9, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the first quarter ended March 31, 2025. First Quarter 2025 Financial and Operating Highlights Gross billings[1] for the first quarter of 2025 were US$21.9 million, a 74.6% growth from the first quarter of 2024.Net revenues were US$18.2 million for the first quarter of 2025, a 93.1% increase from US$9.4 million for the first quarter of 2024.The number of active students with attended lesson consumption was approximately 81,100 in the first quarter of 2025, repres

      6/9/25 6:00:00 AM ET
      $COE
      Other Consumer Services
      Real Estate